These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 503250)

  • 21. [3H]-domperidone labels only a single population of receptors which convert from high to low affinity for dopamine in rat brain.
    Grigoriadis D; Seeman P
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Jan; 332(1):21-5. PubMed ID: 2869417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding sites for [3H]dopamine and dopamine-antagonists on cultured astrocytes of rat striatum and spinal cord: an autoradiographic study.
    Hösli E; Hösli L
    Neurosci Lett; 1986 Apr; 65(2):177-82. PubMed ID: 2940478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine receptor binding for agonists and antagonists in thermal exposed membranes.
    Lew JY; Goldstein M
    Eur J Pharmacol; 1979 May; 55(4):429-30. PubMed ID: 467499
    [No Abstract]   [Full Text] [Related]  

  • 24. Differentiation by ascorbic acid of dopamine agonist and antagonist binding sites in striatum.
    Kayaalp SO; Neff NH
    Life Sci; 1980 Jun; 26(22):1837-41. PubMed ID: 7401904
    [No Abstract]   [Full Text] [Related]  

  • 25. Binding characteristics of the dopamine agonist/antagonist [3H]terguride (transdihydrolisuride) in the rat striatum.
    Valchár M; Vrsecká M; Krejcí I; Dlabac A
    Eur J Pharmacol; 1987 Apr; 136(1):97-101. PubMed ID: 3297739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.
    Niznik HB; Grigoriadis DE; Pri-Bar I; Buchman O; Seeman P
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):333-43. PubMed ID: 2863760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cocaine-induced supersensitivity of striatal dopamine receptors: role of endogenous calmodulin.
    Memo M; Pradhan S; Hanbauer I
    Neuropharmacology; 1981 Dec; 20(12A):1145-50. PubMed ID: 7322289
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of assay conditions in determining agonist potency at D2 dopamine receptors in striatal homogenates.
    de Vries DJ; Beart PM
    Brain Res; 1986 Jul; 387(1):29-35. PubMed ID: 3742232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of some 2-hydroxybenzylpiperidines with dopamine receptors.
    Cardellini M; Claudi F; Perlini V; Balduini W; Cattabeni F; Cimino M
    Farmaco Sci; 1987 Apr; 42(4):307-17. PubMed ID: 3595841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre- and postsynaptic striatal dopamine receptors: differential sensitivity to apomorphine inhibition of [3H]dopamine and [14C]GABA release in vitro.
    Brase DA
    J Pharm Pharmacol; 1980 Jun; 32(6):432-3. PubMed ID: 6106680
    [No Abstract]   [Full Text] [Related]  

  • 31. During one year's neuroleptic treatment in rats striatal dopamine receptor blockade decreases but serum prolactin levels remain elevated.
    Dyer RG; Murugaiah K; Theodorou A; Clow A; Jenner P; Marsden CD
    Life Sci; 1981 Jan; 28(2):167-74. PubMed ID: 6114373
    [No Abstract]   [Full Text] [Related]  

  • 32. Aging brain and dopamine receptors: abnormal regulation by CCK-8 of 3H-spiperone labeled dopamine receptors in striatal membranes.
    Agnati LF; Fuxe K; Battistini N; Benfenati F
    Acta Physiol Scand; 1984 Mar; 120(3):465-7. PubMed ID: 6331074
    [No Abstract]   [Full Text] [Related]  

  • 33. Multiple daily amphetamine administration decreases both [3H]agonist and [3H]antagonist dopamine receptor binding.
    Sibley DR; Weinberger S; Segal DS; Creese I
    Experientia; 1982 Oct; 38(10):1224-5. PubMed ID: 6890464
    [No Abstract]   [Full Text] [Related]  

  • 34. A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.
    Martin GE; Williams M; Haubrich DR
    J Pharmacol Exp Ther; 1982 Nov; 223(2):298-304. PubMed ID: 6813451
    [No Abstract]   [Full Text] [Related]  

  • 35. 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites.
    Coupet J; Rauh CE
    Eur J Pharmacol; 1979 Apr; 55(2):215-8. PubMed ID: 456420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential inhibitory effects of ascorbic acid on the binding of dopamine agonists and antagonists to neostriatal membrane preparations: correlations with behavioral effects.
    Heikkila RE; Cabbat FS; Manzino L
    Res Commun Chem Pathol Pharmacol; 1981 Dec; 34(3):409-21. PubMed ID: 7323442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Striatal dopamine receptors become supersensitive while rats are geven trifluoperazine for six months.
    Clow A; Jenner P; Theodorou A; Marsden CD
    Nature; 1979 Mar; 278(5699):59-61. PubMed ID: 570253
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone.
    Van Nueten JM; Ennis C; Helsen L; Laduron PM; Janssen PA
    Life Sci; 1978 Aug; 23(5):453-7. PubMed ID: 692268
    [No Abstract]   [Full Text] [Related]  

  • 39. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes.
    Hamblin MW; Creese I
    Mol Pharmacol; 1982 Jan; 21(1):44-51. PubMed ID: 6127621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of (-)N-(chloroethyl)-norapomorphine on [3H]-apomorphine binding to striatal dopamine receptors.
    Goosey MW; Doggett NS
    Biochem Pharmacol; 1982 Nov; 31(22):3693-4. PubMed ID: 7181954
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.